Is there a cyclosporin (cyclosporine) shampoo available for treating skin conditions such as psoriasis or atopic dermatitis?

Medical Advisory BoardAll articles are reviewed for accuracy by our Medical Advisory Board
Educational purpose only • Exercise caution as content is pending human review
Article Review Status
Submitted
Under Review
Approved

Last updated: January 26, 2026View editorial policy

Personalize

Help us tailor your experience

Which best describes you? Your choice helps us use language that's most understandable for you.

Cyclosporine Shampoo Availability

No, there is no cyclosporine shampoo formulation available or approved for treating skin conditions such as psoriasis or atopic dermatitis. Cyclosporine is only available as oral formulations (soft gelatin capsules) for dermatologic use, and topical cyclosporine formulations have proven ineffective. 1

Why Topical Cyclosporine Doesn't Work

  • Topical cyclosporine formulations have failed to demonstrate clinical efficacy in controlled studies, with response rates of 50% or less in humans, and no significant improvement found in patients with atopic dermatitis or allergic contact dermatitis. 2

  • The molecular properties of cyclosporine make topical delivery problematic—it is a neutral, hydrophobic, cyclic polypeptide with a molecular weight of 1203 Da, which limits skin penetration. 1

Available Cyclosporine Formulations

Cyclosporine is only available in oral formulations for dermatologic conditions:

  • Microemulsion formulation (Neoral): The preferred formulation with more rapid absorption, consistent bioavailability, and faster onset of action compared to the original formulation. 3, 4

  • Original formulation (Sandimmun): An olive oil-based solution with lower and more variable bioavailability, now largely superseded by the microemulsion. 1

  • Both formulations come as soft gelatin capsules taken orally, divided into two doses daily. 1, 4

Approved Dermatologic Uses

Cyclosporine oral therapy is FDA-approved and highly effective for:

  • Severe chronic plaque psoriasis: Achieving 50-70% PASI 75 response at 2.5-5 mg/kg/day within 8-16 weeks. 5

  • Severe refractory atopic dermatitis: Dosed at 3-5 mg/kg/day for adults with disease uncontrolled by optimized topical treatments and phototherapy. 6

  • The drug is reserved for severe disease as a second-line agent due to its narrow therapeutic index and risks of nephrotoxicity and hypertension. 1

Critical Safety Limitations

Oral cyclosporine requires intensive monitoring and has significant restrictions:

  • Maximum FDA-approved duration is 1 year of continuous treatment, with short-term intermittent courses (8-16 weeks) strongly preferred. 4, 5

  • Mandatory monitoring includes blood pressure and serum creatinine every 2 weeks for the first 3 months, then monthly. 4, 6

  • Nephrotoxicity occurs in up to 71% of patients on long-term therapy, and hypertension develops in 40-57% of patients. 6, 5

Common Pitfall to Avoid

Do not confuse cyclosporine with tacrolimus—while topical tacrolimus (Protopic) is well-established and effective for atopic dermatitis, topical cyclosporine formulations remain ineffective and unavailable. 7 If a patient needs topical calcineurin inhibitor therapy, prescribe tacrolimus ointment, not cyclosporine.

References

Guideline

Guideline Directed Topic Overview

Dr.Oracle Medical Advisory Board & Editors, 2025

Research

Neoral (cyclosporin) in dermatology: technical aspects.

The British journal of dermatology, 1996

Guideline

Cyclosporine Use in Dermatology

Praxis Medical Insights: Practical Summaries of Clinical Guidelines, 2025

Guideline

Cyclosporine Therapy for Chronic Plaque Psoriasis

Praxis Medical Insights: Practical Summaries of Clinical Guidelines, 2025

Guideline

Cyclosporine for Severe Refractory Atopic Dermatitis

Praxis Medical Insights: Practical Summaries of Clinical Guidelines, 2026

Professional Medical Disclaimer

This information is intended for healthcare professionals. Any medical decision-making should rely on clinical judgment and independently verified information. The content provided herein does not replace professional discretion and should be considered supplementary to established clinical guidelines. Healthcare providers should verify all information against primary literature and current practice standards before application in patient care. Dr.Oracle assumes no liability for clinical decisions based on this content.

Have a follow-up question?

Our Medical A.I. is used by practicing medical doctors at top research institutions around the world. Ask any follow up question and get world-class guideline-backed answers instantly.